1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Lesovoy, D.M. Bocharov, E.V. Pustovalova, Y.E. Bocharova, O.V. Arseniev, A.S. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking NE Biochim. Biophys. Acta BBACAQ 0113 0006-3002 1858 1254 1261 10.1016/j.bbamem.2016.02.023 26903218 Alternative packing of EGFR transmembrane domain suggests that protein-lipid interactions underlie signal conduction across membrane. 2016 4733.849 Epidermal growth factor receptor 2.7.10.1 Transmembrane region residues 634-677 2 man polymer Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1 no no EGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKR EGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKR A,B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human sample EGFR, ERBB, ERBB1, HER1 9606 Homo sapiens 469008 Escherichia coli BL21(DE3)pLysS pGEMEX-1/(TRX-tmErbB1) citation citation_author repository Initial release Data collection Database references 1 0 2013-10-30 1 1 2019-06-26 _citation.country _citation.journal_abbrev _citation.journal_id_ASTM _citation.journal_id_CSD _citation.journal_id_ISSN _citation.journal_volume _citation.page_first _citation.page_last _citation.pdbx_database_id_DOI _citation.pdbx_database_id_PubMed _citation.title _citation.year BMRB Y RCSB 2012-10-24 REL REL REL target function 200 20 2D 1H-15N HSQC 2D 1H-15N TROSY 2D 1H-13C constant time HSQC aliphatic 2D 1H-13C constant time HSQC aromatic 3D HNCO 3D HNCA 3D HN(CO)CA 3D HN(CA)CO 3D HNHA 3D HNHB 3D HCCH-TOCSY 3D 1H-15N(TROSY) NOESY 3D 1H-13C NOESY aliphatic 3D 1H-13C(constant time) NOESY aliphatic 15N,13C-F1-filtered/F3-edited-NOESY 15N,13C-F1-filtered/F3-edited-NOESY 0.75 mM [U-99% 13C; U-99% 15N] 0.75 mM 90 mM [U-99% 2H] 0.3 mM 6 mM 10 mM 20 mM 0.75 mM [U-99% 13C; U-99% 15N] 0.75 mM 90 mM [U-99% 2H] 0.3 mM 6 mM 10 mM 20 mM 50 5.0 ambient 313 K simulated annealing, TORSION ANGLE DYNAMICS 1 fewest violations 0.75 mM [U-99% 13C; U-99% 15N] ErbB1tm, 0.75 mM ErbB1tm, 90 mM [U-99% 2H] DPC, 0.3 mM sodium azide, 6 mM TCEP, 10 mM citric acid, 20 mM Na2HPO4, 95% H2O/5% D2O 95% H2O/5% D2O 0.75 mM [U-99% 13C; U-99% 15N] ErbB1tm, 0.75 mM ErbB1tm, 90 mM [U-99% 2H] DPC, 0.3 mM sodium azide, 6 mM TCEP, 10 mM citric acid, 20 mM Na2HPO4, 99.9% D2O 99.9% D2O Guntert, Mumenthaler and Wuthrich structure solution CYANA 3.0 Rochus Keller chemical shift assignment CARA 1.8.4 Wolfram Research data analysis Mathematica Guntert, Mumenthaler and Wuthrich refinement CYANA 3.0 800 Bruker Avance Bruker Avance 600 Bruker Avance Bruker Avance GLU 634 n 1 GLU 634 A GLY 635 n 2 GLY 635 A CYS 636 n 3 CYS 636 A PRO 637 n 4 PRO 637 A THR 638 n 5 THR 638 A ASN 639 n 6 ASN 639 A GLY 640 n 7 GLY 640 A PRO 641 n 8 PRO 641 A LYS 642 n 9 LYS 642 A ILE 643 n 10 ILE 643 A PRO 644 n 11 PRO 644 A SER 645 n 12 SER 645 A ILE 646 n 13 ILE 646 A ALA 647 n 14 ALA 647 A THR 648 n 15 THR 648 A GLY 649 n 16 GLY 649 A MET 650 n 17 MET 650 A VAL 651 n 18 VAL 651 A GLY 652 n 19 GLY 652 A ALA 653 n 20 ALA 653 A LEU 654 n 21 LEU 654 A LEU 655 n 22 LEU 655 A LEU 656 n 23 LEU 656 A LEU 657 n 24 LEU 657 A LEU 658 n 25 LEU 658 A VAL 659 n 26 VAL 659 A VAL 660 n 27 VAL 660 A ALA 661 n 28 ALA 661 A LEU 662 n 29 LEU 662 A GLY 663 n 30 GLY 663 A ILE 664 n 31 ILE 664 A GLY 665 n 32 GLY 665 A LEU 666 n 33 LEU 666 A PHE 667 n 34 PHE 667 A MET 668 n 35 MET 668 A ARG 669 n 36 ARG 669 A ARG 670 n 37 ARG 670 A ARG 671 n 38 ARG 671 A HIS 672 n 39 HIS 672 A ILE 673 n 40 ILE 673 A VAL 674 n 41 VAL 674 A ARG 675 n 42 ARG 675 A LYS 676 n 43 LYS 676 A ARG 677 n 44 ARG 677 A GLU 634 n 1 GLU 634 B GLY 635 n 2 GLY 635 B CYS 636 n 3 CYS 636 B PRO 637 n 4 PRO 637 B THR 638 n 5 THR 638 B ASN 639 n 6 ASN 639 B GLY 640 n 7 GLY 640 B PRO 641 n 8 PRO 641 B LYS 642 n 9 LYS 642 B ILE 643 n 10 ILE 643 B PRO 644 n 11 PRO 644 B SER 645 n 12 SER 645 B ILE 646 n 13 ILE 646 B ALA 647 n 14 ALA 647 B THR 648 n 15 THR 648 B GLY 649 n 16 GLY 649 B MET 650 n 17 MET 650 B VAL 651 n 18 VAL 651 B GLY 652 n 19 GLY 652 B ALA 653 n 20 ALA 653 B LEU 654 n 21 LEU 654 B LEU 655 n 22 LEU 655 B LEU 656 n 23 LEU 656 B LEU 657 n 24 LEU 657 B LEU 658 n 25 LEU 658 B VAL 659 n 26 VAL 659 B VAL 660 n 27 VAL 660 B ALA 661 n 28 ALA 661 B LEU 662 n 29 LEU 662 B GLY 663 n 30 GLY 663 B ILE 664 n 31 ILE 664 B GLY 665 n 32 GLY 665 B LEU 666 n 33 LEU 666 B PHE 667 n 34 PHE 667 B MET 668 n 35 MET 668 B ARG 669 n 36 ARG 669 B ARG 670 n 37 ARG 670 B ARG 671 n 38 ARG 671 B HIS 672 n 39 HIS 672 B ILE 673 n 40 ILE 673 B VAL 674 n 41 VAL 674 B ARG 675 n 42 ARG 675 B LYS 676 n 43 LYS 676 B ARG 677 n 44 ARG 677 B author_defined_assembly 2 dimeric 1072.1 -17.7 9931 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A CYS 636 -159.78 68.85 1 A PRO 641 -69.71 98.56 1 A ILE 643 -119.08 74.75 1 A PRO 644 -69.72 -170.94 1 B CYS 636 -150.27 73.40 1 B ILE 643 -112.61 74.82 1 B PRO 644 -69.81 -171.69 2 A PRO 637 -69.75 76.84 2 A PRO 644 -69.78 -166.09 2 B CYS 636 54.23 73.17 2 B PRO 637 -69.79 85.61 2 B PRO 644 -69.74 -164.89 2 B ILE 673 -58.34 98.29 3 A CYS 636 -154.11 69.76 3 A PRO 644 -69.78 -166.20 3 B CYS 636 -152.58 70.52 3 B PRO 637 -69.79 84.71 3 B THR 638 37.81 42.58 3 B PRO 641 -69.82 -172.36 3 B ILE 643 -114.03 71.91 3 B PRO 644 -69.77 -165.77 3 B HIS 672 -59.41 106.02 4 A PRO 644 -69.80 -165.73 4 A VAL 674 62.41 63.52 4 B CYS 636 -119.50 73.35 4 B PRO 644 -69.76 -164.79 5 A CYS 636 -171.60 73.95 5 A PRO 637 -69.73 87.35 5 A PRO 644 -69.74 -168.91 5 B PRO 644 -69.72 -166.20 5 B VAL 674 -60.37 97.73 6 A PRO 644 -69.81 -168.21 6 A HIS 672 -58.07 98.89 6 B LYS 642 -164.62 -165.17 6 B PRO 644 -69.71 -166.91 7 A PRO 641 -69.81 -170.68 7 A LYS 642 -172.23 146.66 7 A ILE 643 54.05 74.15 7 A PRO 644 -69.74 -169.02 7 A ILE 673 -98.23 -69.91 7 B PRO 641 -69.77 98.82 7 B PRO 644 -69.86 -167.93 7 B HIS 672 -97.87 -67.15 8 A PRO 641 -69.77 88.54 8 A ILE 643 50.26 70.31 8 A PRO 644 -69.75 -165.45 8 B CYS 636 59.68 70.25 8 B PRO 644 -69.72 -165.98 9 A CYS 636 -175.06 73.21 9 A LYS 642 -171.13 142.39 9 A ILE 643 -118.16 71.45 9 A PRO 644 -69.82 -167.52 9 A ILE 673 -62.24 98.17 9 A ARG 675 -90.22 -67.47 9 A LYS 676 -52.13 109.13 9 B CYS 636 -118.42 68.07 9 B PRO 644 -69.76 -169.10 10 A CYS 636 -165.81 69.18 10 A PRO 644 -69.77 -167.83 10 B CYS 636 -155.92 70.39 10 B THR 638 -160.63 87.95 10 B PRO 644 -69.77 -165.57 11 A CYS 636 55.63 74.42 11 A THR 638 -170.08 87.47 11 A PRO 644 -69.75 -167.25 11 B PRO 637 -69.75 75.95 11 B PRO 644 -69.84 -167.56 11 B ARG 671 -80.19 -75.10 12 A CYS 636 57.14 74.15 12 A THR 638 -168.83 86.58 12 A PRO 644 -69.78 -169.27 12 B ILE 643 -115.44 69.99 12 B PRO 644 -69.68 -169.58 12 B ARG 670 48.74 27.94 13 A CYS 636 59.39 71.19 13 A PRO 644 -69.77 -168.80 13 B PRO 637 -69.80 78.55 13 B PRO 644 -69.76 -168.07 14 A PRO 644 -69.80 -168.00 14 B CYS 636 -161.51 73.41 14 B THR 638 -160.41 79.77 14 B PRO 644 -69.79 -169.07 15 A CYS 636 53.04 71.12 15 A THR 638 -164.62 92.28 15 A PRO 644 -69.79 -167.17 15 B CYS 636 -118.38 69.20 15 B PRO 644 -69.81 -169.44 15 B LYS 676 -54.68 172.53 16 A PRO 644 -69.83 -167.97 16 A HIS 672 -53.88 106.71 16 B CYS 636 -154.86 73.73 16 B PRO 637 -69.75 78.94 16 B THR 638 37.37 43.42 16 B ILE 643 61.01 69.75 16 B PRO 644 -69.72 -166.60 16 B LYS 676 -94.82 -68.56 17 A CYS 636 -173.62 68.11 17 A PRO 644 -69.72 -167.69 17 A ARG 675 -81.43 -70.91 17 B CYS 636 56.42 73.82 17 B THR 638 -168.25 73.78 17 B PRO 641 -69.79 -177.55 17 B ILE 643 51.13 70.21 17 B PRO 644 -69.72 -168.26 18 A PRO 641 -69.74 78.03 18 A ILE 643 51.12 73.00 18 A PRO 644 -69.83 -169.29 18 B CYS 636 -118.54 68.20 18 B ILE 643 -113.24 74.25 18 B PRO 644 -69.79 -168.38 18 B HIS 672 -62.65 -170.94 19 A CYS 636 -167.57 68.97 19 A PRO 637 -69.70 80.13 19 A THR 638 37.47 43.30 19 A ILE 643 50.39 70.63 19 A PRO 644 -69.78 -166.29 19 B CYS 636 53.49 72.73 19 B PRO 637 -69.82 92.27 19 B PRO 644 -69.79 -168.34 19 B ILE 673 -59.79 96.80 19 B LYS 676 -58.04 178.99 20 A PRO 637 -69.72 80.15 20 A ILE 643 51.44 74.97 20 A PRO 644 -69.73 -166.24 20 A HIS 672 -51.69 103.17 20 B PRO 637 -69.74 83.82 20 B ILE 643 50.77 72.26 20 B PRO 644 -69.72 -168.29 Epidermal growth factor receptor (E.C.2.7.10.1) fewest violations, model 1 Homodimeric transmembrane domain of the human receptor tyrosine kinase ErbB1 (EGFR, HER1) in micelles 1 N N 1 N N A ILE 646 A ILE 13 HELX_P A ARG 670 A ARG 37 1 1 25 B ILE 646 B ILE 13 HELX_P B ARG 670 B ARG 37 1 2 25 MEMBRANE PROTEIN TRANSMEMBRANE DOMAIN, ERBB1, RECEPTOR, DIMERIZATION, TYROSINE KINASE, MEMBRANE PROTEIN EGFR_HUMAN UNP 1 634 P00533 EGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKR 634 677 2M0B 634 677 P00533 A 1 1 44 634 677 2M0B 634 677 P00533 B 1 1 44